Zobrazeno 1 - 10
of 35
pro vyhledávání: '"Linda R Bressler"'
Autor:
Susan Halabi, Jinyi Zhou, Yijie He, Linda R Bressler, Adrian F Hernandez, Nicholas A Turner, Hwanhee Hong
Publikováno v:
Clinical trials (London, England). 19(5)
Background/Aim The number of coronavirus disease 2019 deaths and cases continues to increase globally. Novel therapies are urgently needed to treat patients with coronavirus disease 2019. We sought to provide a critical review of trials designed duri
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ff072d6b3b75cab79a01c81b7e5c8422
https://pubmed.ncbi.nlm.nih.gov/35786000
https://pubmed.ncbi.nlm.nih.gov/35786000
Autor:
Linda R. Bressler, Katie E. Long, J. Lee Villano, Nathalie Letarte, Michael Gabay, Joan M. Stachnik
Publikováno v:
Journal of Neuro-Oncology. 120:111-115
The EORTC-NCIC regimen for glioblastoma requires different dosing of temozolomide (TMZ) during radiation and maintenance therapy. This complexity is exacerbated by the availability of multiple TMZ capsule strengths. TMZ is an alkylating agent and the
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6ce4aa156e260ab99a9088b9a0fd16bd
https://doi.org/10.1007/s11060-014-1523-1
https://doi.org/10.1007/s11060-014-1523-1
Autor:
Rishi Lulla, Paul G. Fisher, Craig W. Beattie, Shengjie Wu, Girish Dhall, Arzu Onar, Roger J. Packer, Stewart Goldman, Tohru Yamada, Maryam Fouladi, Ira J. Dunkel, Michael J. Pacini, Linda R. Bressler, Ian F. Pollack, James M. Boyett
Background p53 is a promising target in human cancer. p28 is a cell-penetrating peptide that preferentially enters cancer cells and binds to both wild-type and mutant p53 protein, inhibiting COP1-mediated ubiquitination and proteasomal degradation. T
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8a1ad24dac578e918a737cc0662c784b
https://europepmc.org/articles/PMC4999001/
https://europepmc.org/articles/PMC4999001/
Publikováno v:
Annals of Pharmacotherapy. 43:235-241
Background: Serum creatinine (SCr)-based formulas are used to estimate glomerular filtration rate (GFR) when calculating a dosage for carboplatin using the Calvert equation, but these formulas often underestimate measured GFR. The Modified Diet in Re
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::63c1c771601c33dfe384ece6e5a76751
https://doi.org/10.1345/aph.1l446
https://doi.org/10.1345/aph.1l446
Autor:
Joan M. Stachnik, Colleen L. Overley, Michael Gabay, Katie E. Long, Linda R. Bressler, John L. Villano, Scott Wirth
Publikováno v:
CNS drugs. 29(11)
The purpose of our review is to summarize the clinical activity of oral targeted agents against brain metastases. This includes BRAF inhibitors (dabrafenib and vemurafenib), human epidermal growth factor receptor inhibitors (lapatinib, gefitinib, erl
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c52ad23f17d25e5e2de04df216537cdc
https://pubmed.ncbi.nlm.nih.gov/26563196
https://pubmed.ncbi.nlm.nih.gov/26563196
Autor:
Samarth Reddy, Sigrun Hallmeyer, Phillip J. DeChristopher, Nadim Mahmud, Supriya Perambakam, Linda R. Bressler, Rafael Nunez, Delores Mahmud, David Peace, Jeffrey A. Sosman
Publikováno v:
Cancer Immunology, Immunotherapy. 55:1033-1042
T cell immunotherapy of prostate cancer (CaP) offers the potential for less toxic, more effective outcomes. A clinical trial was conducted in 28 patients with locally advanced or metastatic CaP to determine whether an HLA-A2 binding epitope of prosta
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b6562defa4aedd4b62717f3e68295b16
https://doi.org/10.1007/s00262-005-0090-x
https://doi.org/10.1007/s00262-005-0090-x
Autor:
Robert E. Molokie, Donald Lavelle, Mabel Koshy, Linda R. Bressler, Nasrin Talischy, Louise Dorn, Joseph DeSimone
Publikováno v:
Blood. 99:3905-3908
We have previously demonstrated that 5-aza-2'-deoxycytidine (decitabine) augments fetal hemoglobin (HbF) levels in patients with sickle cell anemia (SS) who did not respond to hydroxyurea (HU). The present study was designed to determine the effect o
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ced5e3de30909a87ecbe5e7eadae879d
https://doi.org/10.1182/blood.v99.11.3905
https://doi.org/10.1182/blood.v99.11.3905
Publikováno v:
Cancer Chemotherapy and Pharmacology. 69:1113-1115
The benefit of six cycles of adjuvant temozolomide was documented in a randomized phase III (EORTC-NCIC CE.3) trial, and this therapy, following combined temozolomide and radiation, is the standard of care for patients with newly diagnosed glioblasto
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6fff79ca0454298986f64b50e5a25f3c
https://doi.org/10.1007/s00280-011-1796-4
https://doi.org/10.1007/s00280-011-1796-4
Publikováno v:
Journal of Neuro-Oncology. 87:119-121
We quantify a three day tumor doubling time for small cell lung cancer metastatic to the brain in a case of a 61 yearold woman with a 30 pack-year smoking history. She was diagnosed with extensive stage small cell lung carcinoma with bone metastases
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e1e10f2b402f34f259d148f2a7990320
https://doi.org/10.1007/s11060-007-9496-y
https://doi.org/10.1007/s11060-007-9496-y
Publikováno v:
Anti-Cancer Drugs. 18:827-829
Cetuximab (Erbitux) is a recombinant, chimeric monoclonal antibody that binds with high affinity to the extracellular ligand-binding domain of human epidermal growth factor receptor. We report a case of repeated responses to cetuximab in a patient wi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2cd21754d27caeed9107ed5addd79959
https://doi.org/10.1097/cad.0b013e32809ef9e0
https://doi.org/10.1097/cad.0b013e32809ef9e0